Elena Prokupets - Sep 10, 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Sep 10, 2021
Transactions value $
-$460,985
Form type
4
Date filed
9/14/2021, 04:10 PM
Previous filing
Aug 5, 2021
Next filing
Sep 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Sale -$61.5K -1.23K -1.39% $50.00* 87.3K Sep 10, 2021 By Spouse F1, F2
transaction CCCC Common Stock Sale -$66K -1.32K -0.22% $50.01* 592K Sep 10, 2021 By ERP Business Holdings, LP F2, F3, F4
transaction CCCC Common Stock Sale -$167K -3.33K -3.81% $50.07* 84K Sep 13, 2021 By Spouse F1, F5
transaction CCCC Common Stock Sale -$167K -3.33K -0.56% $50.07* 588K Sep 13, 2021 By ERP Business Holdings, LP F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.
F4 Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.54. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.